ContraFect Corp (NASDAQ:CFRX) Short Interest Down 11.5% in August
ContraFect Corp (NASDAQ:CFRX) was the recipient of a large decrease in short interest in August. As of August 31st, there was short interest totalling 347,500 shares, a decrease of 11.5% from the July 31st total of 392,500 shares. Based on an average trading volume of 487,700 shares, the short-interest ratio is currently 0.7 days. Approximately 0.6% of the company’s stock are sold short.
ContraFect stock traded down $0.01 during mid-day trading on Friday, hitting $0.39. The company’s stock had a trading volume of 9,041 shares, compared to its average volume of 449,140. The firm’s 50 day moving average is $0.40 and its 200 day moving average is $0.46. The company has a market cap of $30.97 million, a PE ratio of -1.07 and a beta of 0.15. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.15 and a quick ratio of 4.15. ContraFect has a 52-week low of $0.27 and a 52-week high of $2.63.
Several brokerages recently issued reports on CFRX. ValuEngine raised ContraFect from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Maxim Group began coverage on ContraFect in a research note on Tuesday, June 11th. They issued a “buy” rating for the company.
ContraFect Company Profile
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Recommended Story: How dollar cost averaging works
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.